sphingolipidosis
Sign in to saveAlso known as Sphingolipidosis (disorder), Sphingolipidosis, NOS, sphingolipidoses
Sphingolipidoses are a class of lipid storage disorders or degenerative storage disorders caused by deficiency of an enzyme that is required for the catabolism of lipids that contain ceramide, also relating to sphingolipid metabolism. The main members of this group are Niemann–Pick disease, Fabry disease, Krabbe disease, Gaucher disease, Tay–Sachs disease and metachromatic leukodystrophy. They are generally inherited in an autosomal recessive fashion, but notably Fabry disease is X-linked recessive. Taken together, sphingolipidoses have an incidence of approximately 1 in 10,000, but substantia
Research
17,765 papers- Therapeutic targeting of neuroinflammation in sphingolipidosis.Molecular immunology · 2025
- [Sphingolipidosis].Fukuoka igaku zasshi = Hukuoka acta medica · 1992
- Niemann-Pick type C disease: The atypical sphingolipidosis.Advances in biological regulation · 2018
- [Biochemical aspects of sphingolipidosis].Annales de biologie clinique · 1972
- [Sphingolipidosis in childhood].La Pediatria · 1968
via PubMed
~4 min read
Encyclopedic overview
6 sectionsContents
- Accumulated products
- Comparison
- Metabolic pathways
- See also
- References
- External links
Sphingolipidoses are a class of lipid storage disorders or degenerative storage disorders caused by deficiency of an enzyme that is required for the catabolism of lipids that contain ceramide, also relating to sphingolipid metabolism. The main members of this group are Niemann–Pick disease, Fabry disease, Krabbe disease, Gaucher disease, Tay–Sachs disease and metachromatic leukodystrophy. They are generally inherited in an autosomal recessive fashion, but notably Fabry disease is X-linked recessive. Taken together, sphingolipidoses have an incidence of approximately 1 in 10,000, but substantially more in certain populations such as Ashkenazi Jews. Enzyme replacement therapy is available to treat mainly Fabry disease and Gaucher disease, and people with these types of sphingolipidoses may live well into adulthood. The other types are generally fatal by age 1 to 5 years for infantile forms, but progression may be mild for juvenile- or adult-onset forms.
==Accumulated products== Gangliosides: Gangliosidosis GM1 gangliosidoses GM2 gangliosidoses Tay–Sachs disease Sandhoff disease GM2-gangliosidosis, AB variant Glycolipids Fabry's disease Krabbe disease Metachromatic leukodystrophy Glucocerebrosides Gaucher's disease
Excerpted from Wikipedia’s “sphingolipidosis” article, available under the CC BY-SA 4.0 licence.